Overview

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the response rate and toxicity of the association R-CHOP with two schedules of administration of Velcade, in B-cell CD 20 + lymphoma patients, aged from 18 to 80 years The goal is to get a response rate at least at what observed with R-CHOP alone and will be evaluates with a sequential test. The other objective is to evaluate the toxicity
Phase:
Phase 2
Details
Lead Sponsor:
Lymphoma Study Association
Collaborator:
Association pour le Développement de la Recherche Clinique et Informatique en Onco-Hématologie
Treatments:
Bortezomib
Rituximab